Oppenheimer Asset Management Inc. Purchases Shares of 22,090 Edwards Lifesciences Corporation $EW

Key Points

• Oppenheimer Asset Management initiated a position in Edwards Lifesciences, purchasing 22,090 shares valued at approximately $2.0 million. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences reported quarterly EPS of $0.78, exceeding estimates of $0.74, while revenue rose 13.6% year over year to $1.74 billion. The company issued Q3 2026 EPS guidance of $0.71–$0.77 and full-year guidance of $2.95–$3.05.
• Analysts maintain a “Moderate Buy” consensus rating, with 17 Buy ratings and six Holds and an average price target of $100.27. Several analysts recently raised their targets, while insiders sold 25,570 shares worth about $2.22 million over the past 90 days.

Oppenheimer Asset Management Inc. purchased a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,090 shares of the medical research company's stock, valued at approximately $1,998,000.

Several other institutional investors have also recently made changes to their positions in EW. Investors Research Corp raised its stake in Edwards Lifesciences by 855.3% during the 2nd quarter. Investors Research Corp now owns 898 shares of the medical research company's stock worth $81,000 after acquiring an additional 804 shares during the period. Handelsbanken Fonder AB boosted its position in shares of Edwards Lifesciences by 22.0% in the second quarter. Handelsbanken Fonder AB now owns 1,541,212 shares of the medical research company's stock worth $139,418,000 after purchasing an additional 278,208 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its position in shares of Edwards Lifesciences by 37.1% in the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 7,208 shares of the medical research company's stock worth $652,000 after purchasing an additional 1,950 shares during the period. Revolve Wealth Partners LLC purchased a new stake in shares of Edwards Lifesciences in the second quarter worth $206,000. Finally, Everpar Advisors LLC purchased a new stake in shares of Edwards Lifesciences in the second quarter worth $267,000. Institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $91.51 on Monday. The stock has a market capitalization of $52.69 billion, a PE ratio of 52.59, a P/E/G ratio of 2.30 and a beta of 0.85. The business has a 50 day simple moving average of $88.73 and a two-hundred day simple moving average of $84.38. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The business had revenue of $1.74 billion for the quarter, compared to analysts' expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company's revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 25,570 shares of company stock worth $2,219,390. Insiders own 0.31% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Piper Sandler restated an "overweight" rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Barclays reaffirmed an "overweight" rating and issued a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Canaccord Genuity Group set a $85.00 price target on Edwards Lifesciences and gave the company a "hold" rating in a report on Friday, April 24th. Citigroup raised their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Finally, Mizuho boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research report on Wednesday, July 15th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source